# Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

> **NCT02440789** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 32 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02440789
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2017-11-02
- **Final completion:** 2018-02-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440789, "Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02440789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*